Point-of-Care Diagnostics includes OPKO’s breakthrough point-of-care platform and a pipeline of novel diagnostic tests, including those for prostate cancer, total PSA, Vitamin D, and Alzheimer’s disease.
OPKO Chile markets and distributes a line of pharmaceuticals, nutraceuticals, and topicals for a wide variety of conditions.
OPKO EU develops, manufactures, markets, and sells a line of pharmaceutical, nutraceutical, and veterinary products throughout Europe.
OPKO FineTech manufactures numerous high-value, complex APIs (active pharmaceutical ingredients), such as latanoprost, bimatoprost, and melatonin.
OPKO Mexico maintains a line of pharmaceuticals, nutraceuticals, and topicals focused on ocular medicine. It is also conducting research on influenza, uterine cancer, and cervical cancer.
Cytochroma: OPKO has gained access to a suite of products for treatment of secondary hyperparathyroidism and hyperphosphatemia in chronic kidney disease patients through its recently announced agreement to acquire all of the assets of Cytochroma, Inc. Cytochroma’s lead products under development include Rayaldy™ and Alpharen™. Rayaldy™, a vitamin D compound, will be marketed along with OPKO’s point-of-care vitamin D diagnostic test.